Published 2025-01-01
“…Liting Zhong,1,2,* Weiwei Peng,1,2,* Jingyuan Sun,3 Yongyi
Luo,3 Hailong Sheng,4 Yi Wu,5 Tonggang Zhou,5 Chaoming Zhou,1,2 Chuanhui Cao1,3 1Department of Oncology, Ganzhou Hospital-Nanfang Hospital, Southern Medical University, Ganzhou, Jiangxi, People’s Republic of China; 2Department of Oncology, Ganzhou People’s Hospital, Ganzhou, Jiangxi, People’s Republic of China; 3Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou,
Guangdong, People’s Republic of China; 4Department of Radiation Oncology, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou, Zhejiang, People’s Republic of China; 5Department of Interventional Radiology, Ganzhou People’s Hospital, Ganzhou, Jiangxi, People’s Republic of China*These authors contributed equally to this workCorrespondence: Chuanhui Cao, Department of Oncology, Ganzhou Hospital-Nanfang Hospital, Southern Medical University, No. 16 Meiguan Avenue, Ganzhou, Jiangxi, People’s Republic of China, Email huichuancao@163.comPurpose: The optimal timing for combining radiotherapy with immunotherapy in patients with hepatocellular carcinoma (HCC) remains uncertain and affects treatment efficacy and patient outcomes. …”
Get full text
Article